Skip to content

Category: Biotechnology

NeuroScientific Biopharmaceuticals Reports Positive Outcomes from StemSmart(TM) MSC Therapy in Renal Transplantation

By API User

NeuroScientific Biopharmaceuticals Reports Positive Outcomes from StemSmart™ MSC Therapy in Renal Transplantation Sydney, Australia – 27 August 2025 – NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) today announced promising results from two clinical studies evaluating its proprietary StemSmart™ mesenchymal stromal cell (MSC) therapy in renal transplantation. The findings provide strong support for further clinical development aimed at improving … Continued

BlinkLab Expands U.S. Clinical Trial Network with Top-Ranked Pediatric Institutions Ahead of FDA Submission

By API User

Perth, Australia – 26 August 2025 – BlinkLab Limited (ASX:BB1), a digital health company developing AI-powered smartphone-based diagnostic tools for neurodevelopmental conditions, today announced the expansion of its U.S. clinical trial network with the addition of two globally renowned institutions: Cincinnati Children’s Medical Center and Seattle Children’s Research Institute. Both centres will participate in BlinkLab’s … Continued

LTR Pharma’s SPONTAN® Treatment for Erectile Dysfunction Demonstrates 100% Patient Satisfaction in Post-Prostatectomy Study

By API User

25 August 2025 – Sydney, Australia | LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) today announced highly encouraging results from a case series that is evaluating the efficacy of its intranasal erectile dysfunction therapy, SPONTAN®, in men recovering from radical prostatectomy. The results, presented at the 25th Asia-Pacific Prostate Cancer Conference (APCC) in … Continued

LTR Pharma Announces SPONTAN® Achieves 18-Month Shelf Life

By API User

22 August 2025 | Sydney, Australia – LTR Pharma Limited (ASX:LTP) today announced that SPONTAN® has achieved an 18-month shelf life under international pharmaceutical stability standards, a key milestone that strengthens the product’s commercial potential in the global erectile dysfunction market, forecast to reach US$6.0 billion by 2028. This achievement demonstrates the robustness of SPONTAN’s formulation, … Continued

Velos to accelerate medical innovation in the Monash Technology Precinct

By API User

Key points $17.5 million from the Victorian Government has enabled the Monash Velos Accelerator  Velos will focus on cardiovascular, kidney and metabolic disease It will foster collaboration and commercialisation of medical innovation A new Monash Technology Precinct accelerator focussing on cardiovascular, kidney and metabolic diseases will help transform medical innovation ideas into reality. Monash Velos … Continued

Velos to accelerate medical innovation in the Monash Technology Precinct

By API User

Key points $17.5 million from the Victorian Government has enabled the Monash Velos Accelerator  Velos will focus on cardiovascular, kidney and metabolic disease It will foster collaboration and commercialisation of medical innovation A new Monash Technology Precinct accelerator focussing on cardiovascular, kidney and metabolic diseases will help transform medical innovation ideas into reality. Monash Velos … Continued

LTR Pharma Clinical Study Published in Leading European Journal Validates Rapid Onset for Nasal Erectile Dysfunction Therapy

By API User

20 August 2025 | Sydney, Australia – LTR Pharma Limited (ASX:LTP) is pleased to announce a peer-reviewed publication of clinical data from its Phase I pharmacokinetic study of SPONTAN®, the Company’s flagship intranasal formulation for erectile dysfunction (ED). The data has been published in the European Journal of Pharmaceutical Sciences, which is a highly regarded … Continued

Peter Beattie AC appointed Brandon BioCatalyst Chair

By API User

Melbourne, Australia Tuesday, 19 August 2025: Brandon BioCatalyst, a collaboration of more than 50 of Australia and New Zealand’s leading medical research institutes, hospitals and universities, today announced new board appointments to continue the scaling of Australian medical research into globally competitive biotech companies.   The board transition sees the appointment of long-standing director and … Continued

Cartherics unveils state-of-the-art cleanroom facility for cell therapy manufacturing

By API User

Melbourne, Australia, 6 August 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune stem cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products. The facility was officially opened by the … Continued